MannKind Competitors

MannKind (NASDAQ:MNKD) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Earnings & Valuation

This table compares MannKind and Amgen's gross revenue, earnings per share (EPS) and valuation.

Amgen has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for MannKind and Amgen, as reported by MarketBeat.

MannKind presently has a consensus price target of $6.30, suggesting a potential upside of 46.17%. Amgen has a consensus price target of $255.6190, suggesting a potential upside of 1.69%. Given MannKind's stronger consensus rating and higher probable upside, research analysts plainly believe MannKind is more favorable than Amgen.

Profitability

This table compares MannKind and Amgen's net margins, return on equity and return on assets.

Volatility & Risk

MannKind has a beta of 2.28, meaning that its stock price is 128% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.

Insider and Institutional Ownership

29.6% of MannKind shares are owned by institutional investors. Comparatively, 75.2% of Amgen shares are owned by institutional investors. 1.1% of MannKind shares are owned by insiders. Comparatively, 0.4% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Amgen beats MannKind on 9 of the 14 factors compared between the two stocks.

MannKind (NASDAQ:MNKD) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Earnings & Valuation

This table compares MannKind and Gilead Sciences' gross revenue, earnings per share (EPS) and valuation.

Gilead Sciences has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for MannKind and Gilead Sciences, as reported by MarketBeat.

MannKind presently has a consensus price target of $6.30, suggesting a potential upside of 46.17%. Gilead Sciences has a consensus price target of $100.5909, suggesting a potential upside of 46.78%. Given Gilead Sciences' higher probable upside, analysts plainly believe Gilead Sciences is more favorable than MannKind.

Profitability

This table compares MannKind and Gilead Sciences' net margins, return on equity and return on assets.

Volatility & Risk

MannKind has a beta of 2.28, meaning that its stock price is 128% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500.

Insider and Institutional Ownership

29.6% of MannKind shares are owned by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are owned by institutional investors. 1.1% of MannKind shares are owned by insiders. Comparatively, 0.1% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Gilead Sciences beats MannKind on 10 of the 14 factors compared between the two stocks.

MannKind (NASDAQ:MNKD) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Earnings & Valuation

This table compares MannKind and Vertex Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for MannKind and Vertex Pharmaceuticals, as reported by MarketBeat.

MannKind presently has a consensus price target of $6.30, suggesting a potential upside of 46.17%. Vertex Pharmaceuticals has a consensus price target of $293.4737, suggesting a potential upside of 35.19%. Given MannKind's higher probable upside, research analysts plainly believe MannKind is more favorable than Vertex Pharmaceuticals.

Profitability

This table compares MannKind and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Volatility & Risk

MannKind has a beta of 2.28, meaning that its stock price is 128% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.

Insider and Institutional Ownership

29.6% of MannKind shares are owned by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. 1.1% of MannKind shares are owned by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Vertex Pharmaceuticals beats MannKind on 11 of the 15 factors compared between the two stocks.

MannKind (NASDAQ:MNKD) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Earnings & Valuation

This table compares MannKind and Regeneron Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for MannKind and Regeneron Pharmaceuticals, as reported by MarketBeat.

MannKind presently has a consensus price target of $6.30, suggesting a potential upside of 46.17%. Regeneron Pharmaceuticals has a consensus price target of $656.3810, suggesting a potential upside of 27.05%. Given MannKind's stronger consensus rating and higher probable upside, research analysts plainly believe MannKind is more favorable than Regeneron Pharmaceuticals.

Profitability

This table compares MannKind and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Volatility & Risk

MannKind has a beta of 2.28, meaning that its stock price is 128% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500.

Insider and Institutional Ownership

29.6% of MannKind shares are owned by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. 1.1% of MannKind shares are owned by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Regeneron Pharmaceuticals beats MannKind on 10 of the 14 factors compared between the two stocks.

MannKind (NASDAQ:MNKD) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Earnings & Valuation

This table compares MannKind and Biogen's gross revenue, earnings per share (EPS) and valuation.

Biogen has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for MannKind and Biogen, as reported by MarketBeat.

MannKind presently has a consensus price target of $6.30, suggesting a potential upside of 46.17%. Biogen has a consensus price target of $305.5714, suggesting a potential upside of 9.05%. Given MannKind's stronger consensus rating and higher probable upside, research analysts plainly believe MannKind is more favorable than Biogen.

Profitability

This table compares MannKind and Biogen's net margins, return on equity and return on assets.

Volatility & Risk

MannKind has a beta of 2.28, meaning that its stock price is 128% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.

Insider and Institutional Ownership

29.6% of MannKind shares are owned by institutional investors. Comparatively, 83.5% of Biogen shares are owned by institutional investors. 1.1% of MannKind shares are owned by insiders. Comparatively, 0.5% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Biogen beats MannKind on 9 of the 14 factors compared between the two stocks.

MannKind (NASDAQ:MNKD) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Earnings & Valuation

This table compares MannKind and Alexion Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

29.6% of MannKind shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 1.1% of MannKind shares are owned by insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares MannKind and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Volatility & Risk

MannKind has a beta of 2.28, meaning that its stock price is 128% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for MannKind and Alexion Pharmaceuticals, as reported by MarketBeat.

MannKind presently has a consensus price target of $6.30, suggesting a potential upside of 46.17%. Alexion Pharmaceuticals has a consensus price target of $159.3158, suggesting a potential downside of 8.17%. Given MannKind's stronger consensus rating and higher probable upside, research analysts plainly believe MannKind is more favorable than Alexion Pharmaceuticals.

Summary

Alexion Pharmaceuticals beats MannKind on 9 of the 13 factors compared between the two stocks.